X
Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
(BICN)
Here is the latest financial fact sheet of Biocon Ltd. For more details, see the Biocon Ltd quarterly results and Biocon Ltd share price and chart. For a sector overview, read our pharmaceuticals sector report.
| % ch | % | -0.7 |
| No. of shares | m | 600.00 |
| % ch week | % | -2.6 |
| % ch 1-mth | % | 4.5 |
| % ch 12-mth | % | 37.7 |
| 52 week H/L | Rs | 396.0/229.7 |
| No. of Mths Year Ending |
12 Mar-12* |
12 Mar-13* |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
5-Yr Chart Click to enlarge
|
|---|
| BIOCON LTD EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 385 | 307 | 497 | 554 | 496 | |
| Low | Rs | 243 | 211 | 265 | 407 | 397 | |
| Sales per share (Unadj.) | Rs | 104.3 | 124.3 | 143.9 | 154.5 | 174.3 | |
| Earnings per share (Unadj.) | Rs | 16.9 | 25.4 | 20.7 | 24.9 | 44.8 | |
| Diluted earnings per share | Rs | 5.6 | 8.5 | 6.9 | 8.3 | 14.9 | |
| Cash flow per share (Unadj.) | Rs | 25.6 | 34.4 | 30.9 | 35.9 | 56.9 | |
| Dividends per share (Unadj.) | Rs | 5.00 | 7.50 | 5.00 | 5.00 | 5.00 | |
| Adj. dividends per share | Rs | 1.67 | 2.50 | 1.67 | 1.67 | 1.67 | |
| Dividend yield (eoy) | % | 1.6 | 2.9 | 1.3 | 1.0 | 1.1 | |
| Book value per share (Unadj.) | Rs | 113.6 | 134.7 | 151.3 | 163.5 | 202.8 | |
| Adj. book value per share | Rs | 37.9 | 44.9 | 50.4 | 54.5 | 67.6 | |
| Shares outstanding (eoy) | m | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 | |
| Bonus/Rights/Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 3.0 | 2.1 | 2.6 | 3.1 | 2.6 | |
| Avg P/E ratio | x | 18.6 | 10.2 | 18.4 | 19.3 | 10.0 | |
| P/CF ratio (eoy) | x | 12.2 | 7.5 | 12.3 | 13.4 | 7.8 | |
| Price / Book Value ratio | x | 2.8 | 1.9 | 2.5 | 2.9 | 2.2 | |
| Dividend payout | % | 29.6 | 29.5 | 24.2 | 20.1 | 11.2 | |
| Avg Mkt Cap | Rs m | 62,800 | 51,790 | 76,190 | 96,080 | 89,220 | |
| No. of employees | `000 | 6.3 | 6.7 | 7.3 | 7.5 | 4.4 | |
| Total wages/salary | Rs m | 3,076 | 3,894 | 4,663 | 5,334 | 6,363 | |
| Avg. sales/employee | Rs Th | 3,336.8 | 3,694.5 | 3,936.1 | 4,119.7 | 7,894.5 | |
| Avg. wages/employee | Rs Th | 491.9 | 578.9 | 637.9 | 711.2 | 1,441.2 | |
| Avg. net profit/employee | Rs Th | 541.2 | 756.5 | 566.1 | 663.2 | 2,029.7 | |
| BIOCON LTD INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 20,865 | 24,853 | 28,773 | 30,898 | 34,854 | |
| Other income | Rs m | 618 | 527 | 559 | 531 | 845 | |
| Total revenues | Rs m | 21,483 | 25,380 | 29,332 | 31,429 | 35,699 | |
| Gross profit | Rs m | 5,173 | 5,430 | 6,871 | 6,958 | 8,200 | |
| Depreciation | Rs m | 1,744 | 1,793 | 2,036 | 2,210 | 2,423 | |
| Interest | Rs m | 122 | 81 | 17 | 89 | 102 | |
| Profit before tax | Rs m | 3,925 | 4,083 | 5,377 | 5,190 | 6,520 | |
| Minority Interest | Rs m | 0 | -38 | -170 | -310 | -744 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 2,019 | 0 | 1,051 | 5,754 | |
| Tax | Rs m | 541 | 975 | 1,069 | 957 | 2,569 | |
| Profit after tax | Rs m | 3,384 | 5,089 | 4,138 | 4,974 | 8,961 | |
| Gross profit margin | % | 24.8 | 21.8 | 23.9 | 22.5 | 23.5 | |
| Effective tax rate | % | 13.8 | 23.9 | 19.9 | 18.4 | 39.4 | |
| Net profit margin | % | 16.2 | 20.5 | 14.4 | 16.1 | 25.7 | |
| BIOCON LTD BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 19,997 | 22,400 | 26,388 | 25,626 | 39,932 | |
| Current liabilities | Rs m | 10,158 | 9,899 | 13,796 | 15,547 | 16,276 | |
| Net working cap to sales | % | 47.2 | 50.3 | 43.8 | 32.6 | 67.9 | |
| Current ratio | x | 2.0 | 2.3 | 1.9 | 1.6 | 2.5 | |
| Inventory Days | Days | 66 | 59 | 48 | 53 | 54 | |
| Debtors Days | Days | 86 | 75 | 76 | 91 | 86 | |
| Net fixed assets | Rs m | 16,600 | 18,228 | 27,308 | 33,065 | 39,101 | |
| Share capital | Rs m | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | |
| "Free" reserves | Rs m | 20,745 | 24,079 | 27,047 | 30,778 | 38,591 | |
| Net worth | Rs m | 22,724 | 26,946 | 30,267 | 32,706 | 40,556 | |
| Long term debt | Rs m | 698 | 1,640 | 6,062 | 7,696 | 20,724 | |
| Total assets | Rs m | 39,372 | 44,161 | 57,506 | 63,754 | 84,816 | |
| Interest coverage | x | 33.2 | 51.4 | 317.3 | 59.3 | 64.9 | |
| Debt to equity ratio | x | 0 | 0.1 | 0.2 | 0.2 | 0.5 | |
| Sales to assets ratio | x | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 | |
| Return on assets | % | 8.9 | 11.7 | 7.2 | 7.9 | 10.7 | |
| Return on equity | % | 14.9 | 18.9 | 13.7 | 15.2 | 22.1 | |
| Return on capital | % | 17.3 | 21.5 | 14.4 | 14.9 | 19.0 | |
| Exports to sales | % | 31.9 | 38.0 | 37.1 | 33.5 | 30.7 | |
| Imports to sales | % | 21.5 | 22.4 | 22.8 | 19.7 | 20.4 | |
| Exports (fob) | Rs m | 6,661 | 9,450 | 10,669 | 10,339 | 10,717 | |
| Imports (cif) | Rs m | 4,481 | 5,561 | 6,573 | 6,102 | 7,105 | |
| Fx inflow | Rs m | 6,773 | 9,906 | 10,803 | 10,993 | 11,789 | |
| Fx outflow | Rs m | 5,449 | 6,330 | 7,715 | 7,371 | 8,393 | |
| Net fx | Rs m | 1,324 | 3,576 | 3,088 | 3,622 | 3,396 | |
| BIOCON LTD CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 5,641 | 4,712 | 5,607 | 2,107 | 5,264 | |
| From Investments | Rs m | -3,595 | -3,758 | -9,381 | -5,087 | -9,540 | |
| From Financial Activity | Rs m | -1,863 | -86 | 4,260 | 1,862 | 10,867 | |
| Net Cashflow | Rs m | 183 | 868 | 486 | -1,118 | 6,591 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Kiran Mazumdar Shaw (MD) | COMP SEC: Kiran Kumar | YEAR OF INC: 1978 | BSE CODE: 532523 | FV (Rs): 5 | DIV YIELD (%): 0.5 |
More Pharmaceuticals Company Fact Sheets: INDOCO REMEDIES FRESENIUS KABI ONCO. ASTRAZENECA PHARMA MERCK LTD FULFORD INDIA
Compare BIOCON LTD With: INDOCO REMEDIES FRESENIUS KABI ONCO. ASTRAZENECA PHARMA MERCK LTD FULFORD INDIA
Compare BIOCON LTD With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.
Net Profit lower due to exceptional items in the previous year.
Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.
Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.
US markets decline while other geographies grow in the quarter.
Currency fluctuation and one time provision impacts operating margins.
More Views on NewsTomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?
Whether you're Venezuela or China or in India or the US...and you want to protect your wealth, you need real money. All the government has on offer is funny money.
Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.
In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.
Various costs associated with a home loan.
More|
| |
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
